Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

|<

<

1

2

3

4

5

6

7

8

9

10

11

>

>|

Found 44 Matches

Digoxin_V12R2_Simcyp_20150702
Model Files Publication
For the file, ADAM and permeability-ltd liver models were used together with the full-PBPK and Rodgers and Rowland method. The file was evaluated using the Jalava et al. 1997 PK data as overlay.
Search Score: 1
Piperaquine
Model Files Publication

Brand Name(s) include: Eurartesim

Disease: Malaria

Drug Class: Antimalarials

Date Updated: January 2022

Related Files: DHA (partner in fixed dose combination)

The model at-a-glance

  Absorption Model
  • First-Order (dose and food-dependent fa – saved in different models)

  Volume of Distribution

  • Full PBPK (Method 2)
  • Notes: Includes a Kp scalar and Kpadipose

  Route of Elimination
  • CYP3A4 (80%), CYP2C9 (10%), CYP2C19 (10%)

  Perpetrator DDI
  • CYP3A4 Inhibitor

  Validation

  • Two clinical studies with fasted and fed groups at varying dose levels describing single and multiple dose exposure of piperaquine were used to verify the PBPK model. All of the simulated studies were within 1.5-fold of the observed values. 
  • A clinical DDI study where piperaquine was the victim of a CYP3A4-mediated DDI was accurately recovered using the PBPK model as well as a CYP3A4 perpetrator DDI with the sensitive substrate midazolam.

  Limitations
  • Requires separate files for low and high dose due to dose-dependant fa​
  • Cmax overprediction, likely due to formulation differences​
  • Additional verification for DDIs would be ideal although studies are currently not available in literature

  Updates in V19
  • Updated in vitro­ data
  • LogP
  • Converted model to full PBPK with Vss predicted through Method 2

 

Search Score: 1
Bosutinib_V18R2_Pfizer_20240809
Model Files Publication

The Bosutinib model uses a full PBPK distribution model (Method 2) and ADAM, where intestinal P-gp is accounted for (Km=0.38 uM, Jmax = 15.45 pmol/min/cm­2, RAF = 4). The elimination is described via HLM clearance and assigned to CYP3A4, and a user defined renal clearance. An Immediate Release formulation is simulated with a user-defined solubility-pH profile. The performance of the file is described in Yamazaki et al., 2018 (Application of Physiologically Based Pharmacokinetic Modeling in Understanding Bosutinib Drug-Drug Interactions: Importance of Intestinal P-Glycoprotein - PubMed (nih.gov). In a follow-up paper using V18R2, the inputs for intestinal P-gp were updated (Km = 0.58 uM, Jmax = 67.4 pmol/min/cm­2, REF = 1) based on Caco-2 data analysed in SIVA (Pan et al., 2021, Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P-glycoprotein-cytochrome P450 3A4 dual substrates - PubMed (nih.gov)).

Search Score: 1
Acyclovir_MechKiM_V16R1_UniversityOfManchester_20210421
Model Files Publication
https://doi.org/10.1124/jpet.118.251413 Acyclovir compound file with MechKiM. The Acyclovir file was verified with IV data.
Search Score: 1

|<

<

1

2

3

4

5

6

7

8

9

10

11

>

>|